Abstract
Free access to this special issue has been made possible by the financial support of the 1st Annual Treatment as Prevention (TasP) Workshop, held May 4-6, 2011 in Vancouver, British Columbia (BC), Canada. The Workshop was organised and hosted by the BC Centre for Excellence in HIV/AIDS and co-hosted by the International AIDS Society, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the World Health Organization and the National Institute on Drug Abuse. Co-sponsors include the National Institutes of Health Office of AIDS Research, the National Institute of Allergy and Infectious Diseases, the United States President’s Emergency Plan for AIDS Relief (PEPFAR), the Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS), the Bill & Melinda Gates Foundation, the Canadian Institutes for Health Research and the Public Health Agency of Canada. Academic partners included the University of British Columbia, Simon Fraser University, Vancouver Coastal Health Authority and Providence Health Care, Vancouver. Industry sponsors included Bristol- Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. Additional Industry supporters included Abbott Laboratories and Biolytical.
Current HIV Research
Title: Acknowledgements and Editorial (Exploring the Role of “Treatment as Prevention”)
Volume: 9 Issue: 6
Author(s): Marianne Harris and Julio S.G. Montaner
Affiliation:
Abstract: Free access to this special issue has been made possible by the financial support of the 1st Annual Treatment as Prevention (TasP) Workshop, held May 4-6, 2011 in Vancouver, British Columbia (BC), Canada. The Workshop was organised and hosted by the BC Centre for Excellence in HIV/AIDS and co-hosted by the International AIDS Society, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the World Health Organization and the National Institute on Drug Abuse. Co-sponsors include the National Institutes of Health Office of AIDS Research, the National Institute of Allergy and Infectious Diseases, the United States President’s Emergency Plan for AIDS Relief (PEPFAR), the Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS), the Bill & Melinda Gates Foundation, the Canadian Institutes for Health Research and the Public Health Agency of Canada. Academic partners included the University of British Columbia, Simon Fraser University, Vancouver Coastal Health Authority and Providence Health Care, Vancouver. Industry sponsors included Bristol- Myers Squibb, Boehringer Ingelheim, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. Additional Industry supporters included Abbott Laboratories and Biolytical.
Export Options
About this article
Cite this article as:
Harris Marianne and S.G. Montaner Julio, Acknowledgements and Editorial (Exploring the Role of “Treatment as Prevention”), Current HIV Research 2011; 9 (6) . https://dx.doi.org/10.2174/157016211798038560
DOI https://dx.doi.org/10.2174/157016211798038560 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advancement in Vaccinology: New Era in Formulation Strategies
Current Drug Therapy Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis
Current Pharmaceutical Design Tuberculosis: Current Treatment and New Drug Development
Anti-Infective Agents in Medicinal Chemistry Interactions Between Proteins and Platinum-Containing Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry Advances in Research on Pharmacological Activities and Synthesis of Oleanolic Acid Derivatives at C-3 Position
The Natural Products Journal The Gut Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design Thiocoumarins and Dithiocoumarins: Advances in Synthesis and Pharmacological Activity
Current Organic Chemistry Novel Azole-Functionalited Flouroquinolone Hybrids: Design, Conventional and Microwave Irradiated Synthesis, Evaluation as Antibacterial and Antioxidant Agents
Letters in Drug Design & Discovery Computational Approaches for Fragment-Based and De Novo Design
Current Topics in Medicinal Chemistry Ascaris lumbricoides: An Overview of Therapeutic Targets
Infectious Disorders - Drug Targets Anti-Infective Action of Immuno-modulating Polysaccharides (β-Glucan and Plantago Major L. Pectin) against Intracellular (Mycobacteria sp.) and Extracellular (Streptococcus Pneumoniae sp.) Respiratory Pathogens
Current Medicinal Chemistry - Anti-Infective Agents Crystal Engineering to Design of Solids: From Single to Multicomponent Organic Materials
Mini-Reviews in Organic Chemistry Evaluation of the Combined Therapy of DA-7218, a New Oxazolidinone, and Trimethoprim/ Sulfamethoxazole in the Treatment of Experimental Actinomycetoma by Nocardia brasiliensis
Current Drug Delivery The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Present Status and Future Prospects of Chemotherapeutics for Intractable Infections due to Mycobacterium avium Complex
Current Drug Discovery Technologies Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience The Seattle Structural Genomics Center for Infectious Disease (SSGCID)
Infectious Disorders - Drug Targets Antibacterial Activity of Lipophilic Fluoroquinolone Derivatives
Medicinal Chemistry Biodegradable Polymeric Nanoparticles as the Delivery Carrier for Drug
Current Drug Delivery Patent Selections
Recent Patents on Nanomedicine